- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07565662
Intrathecal Dexmedetomidine and Acute Neuropathic Pain After Lower Limb Amputation (DEX-RCT)
Intrathecal Dexmedetomidine Reduces Acute Neuropathic Pain After Lower Limb Amputation: A Randomized Controlled Trial
This randomized controlled trial evaluated the effect of adding intrathecal dexmedetomidine (10 µg) to hyperbaric bupivacaine (11 mg) for spinal anesthesia in patients undergoing lower limb amputation. Thirty patients (ASA I-III) scheduled for elective supra- or infracondylar amputation were randomly allocated to two groups: Control Group (n=15) received hyperbaric bupivacaine 11 mg plus saline 0.9%, and Experimental Group (n=15) received hyperbaric bupivacaine 11 mg plus dexmedetomidine 10 µg. Primary outcomes were duration of motor and sensory neuraxial block and postoperative analgesia at 48 hours. As a prespecified exploratory secondary outcome, incidence of acute neuropathic pain was assessed using the DN4 screening tool at 48 hours. The study was conducted at the Hospital Regional de Alta Especialidad Dr. Juan Graham Casasús, Villahermosa, Tabasco, Mexico, from 30 September to 15 December 2025. Ethics approval was obtained from the Institutional Review Board (CEI/JGC/C02-25) prior to patient enrollment.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Tabasco
-
Villahermosa, Tabasco, Mexico, 86126
- Hospital Regional de Alta Especialidad Dr. Juan Graham Casasus
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients scheduled for elective supra- or infracondylar lower limb amputation
- Age 18 to 65 years
- ASA physical status I-III
- Acceptance of neuraxial anesthetic technique
Exclusion Criteria:
-
Patient refusal of anesthetic procedure
- Prolonged coagulation times
- Anatomical abnormalities of the spine
- ASA IV classification
- Atrioventricular block grade 2 or 3 without pacemaker
- Neurological deterioration (Glasgow score less than 8)
- Hemodynamic instability
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Control Group - Bupivacaine Alone
Patients in this arm received hyperbaric bupivacaine 0.5% 11 mg plus saline 0.9% 0.1 ml administered intrathecally via spinal injection at level L2-L3. Total volume: 2.3 ml. |
Hyperbaric bupivacaine 0.5% 11 mg plus saline 0.9% 0.1 ml administered intrathecally. Total volume 2.3 ml. |
|
Eksperimentell: Experimental Group - Bupivacaine plus Dexmedetomidine
Patients in this arm received hyperbaric bupivacaine 0.5% 11 mg plus dexmedetomidine 10 µg administered intrathecally via spinal injection at level L2-L3. Total volume: 2.3 ml. |
Hyperbaric bupivacaine 0.5% 11 mg plus dexmedetomidine 10 µg administered intrathecally. Total volume 2.3 ml. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion Requiring Analgesic Rescue
Tidsramme: 48 hours postoperatively
|
Proportion of patients requiring at least one analgesic rescue dose during the postoperative period. |
48 hours postoperatively
|
|
Duration of Motor Block
Tidsramme: 48 hours postoperatively
|
Duration of motor block assessed by modified Bromage scale (0-3, higher scores indicate greater motor block). Measured at multiple timepoints through 48 hours postoperatively. |
48 hours postoperatively
|
|
Duration of Sensory Block
Tidsramme: 48 hours postoperatively
|
Duration of sensory block assessed by Hollmen scale. Measured at multiple timepoints through 48 hours postoperatively. |
48 hours postoperatively
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Acute Neuropathic Pain
Tidsramme: 48 hours postoperatively
|
Incidence of acute neuropathic pain assessed by DN4 screening tool (0-10, score ≥4 indicates neuropathic pain component). Reported as exploratory secondary outcome. |
48 hours postoperatively
|
|
Heart Rate
Tidsramme: 4 hours postoperatively
|
Heart rate measured in beats per minute during the first 4 hours post-block. |
4 hours postoperatively
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Gabriel López-Ramírez, PhD, Universidad Juárez Autónoma de Tabasco
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Smerte
- Nevrologiske manifestasjoner
- Sykdommer i nervesystemet
- Postoperative komplikasjoner
- Patologiske prosesser
- Nevromuskulære sykdommer
- Sykdommer i det perifere nervesystemet
- Nevroatferdsmanifestasjoner
- Perseptuelle forstyrrelser
- Smerter, postoperativt
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Nevralgi
- Fantomlem
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Azoler
- Imidazoles
- Uorganiske kjemikalier
- Klorforbindelser
- Natriumforbindelser
- Klorider
- Saltsyre
- Dexmedetomidin
- Natriumklorid
Andre studie-ID-numre
- JI-PG348
- CEI/JGC/C02-25 (Annen identifikator: HRAE Dr. Juan Graham Casasus)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
De-identified individual participant data underlying the published results will be available from the corresponding author on reasonable request.
IPD-delingstidsramme
Data will be available beginning 3 months after article publication and ending 5 years after publication.
Tilgangskriterier for IPD-deling
De-identified individual participant data will be shared with researchers who provide a methodologically sound proposal, approved by the corresponding author, for the purpose of verifying the published results or conducting individual-participant-data meta-analysis. Requests should be directed to the corresponding author.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .